LOEP recommended as treatment option for patients at very high risk of hip fragility fractures

A recent position paper by a working group organized by the International Osteoporosis Foundation (IOF) and the European Society on the Clinical and Economic Aspects of Osteoporosis (ESCEO) defined the risk threshold for patients to be considered for available systemic and local treatments, including a Local Osteo-Enhancement Procedure (LOEP). The risk threshold varies by age and gender and can be determined using the FRAX risk assessment tool. The risk level of the potential treatment group for LOEP is the same as that being suggested for anabolic therapy. You can read more about the treatment selection algorithm here

Read more

AGN1 LOEP proof-of-concept clinical study published in Osteoporosis International

This proof-of-concept clinical study was conducted at Copley Hospital in Morrisville, Vermont (U.S.) and followed 12 women with postmenopausal osteoporosis of the hip for up to seven years following treatment of one hip with AGN1 LOEP.  

 

Read more

AgNovos Healthcare at DKOU in Berlin from October 22nd - 25th, 2019

AgNovos Healthcare will again be exhibiting the CE-marked OSSURE® LOEP® Kit at DKOU in Berlin from October 22nd to 25th, 2019. This year features an exciting lecture (AB66 - 597) about local osteo-enhancement in osteoporotic vertebral bodies on Friday, 25th October at 10:03 in the Dublin Room.

 

Read more

AgNovos Healthcare participated at WCO in Paris from April 4th - 7th, 2019

AgNovos Healthcare is proud having supported again this year together with ESCEO young investigators with grants and presenting exciting data at POSTER VIEWING SESSION III as well as during the SCIENTIFIC SESSION VII.

Read more

Archive

Category